Skip to main content

Search articles in Clinical Research

Found 241 articles

  • Labcorp Launches Global Trial Connect to Accelerat

    Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

    • 18 Jun 2024
    • Editor

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.

  • Moderna's Investigational Therapeutic for Methylma

    Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

    • 7 Jun 2024
    • Editor

    Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency.

  • AbbVie Advances Oncology Pipeline With Start of Mu

    AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

    • 6 Jun 2024
    • Editor

    AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study.

  • Gilead’s Seladelpar Demonstrated a Sustained and C

    Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

    • 6 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease.

  • Gilead Sciences Advances Enrollment in Collaborati

    Gilead Sciences Advances Enrollment in Collaborative Studies to Assess Twice-Yearly HIV Prevention Option for Both Cisgender Women in the U.S. and People Who Inject Drugs in the U.S.

    • 5 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company is advancing enrollment in two groundbreaking collaborative studies to evaluate the tolerability of an investigational long-acting HIV prevention option in groups of people in the United States who are disproportionately affected by HIV but who are often underrepresented in HIV clinical trials.

  • Thermo Fisher Scientific Introduces Innovative Mas

    Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

    • 4 Jun 2024
    • Editor

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

  • New results from rilzabrutinib phase 2 study show

    New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

    • 23 May 2024
    • Editor

    Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma.

  • GSK announces positive results from phase III seve

    GSK announces positive results from phase III severe asthma trials of depemokimab

    • 21 May 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count.

  • Allucent Receives BARDA-Funded Project NextGen Awa

    Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial

    • 16 May 2024
    • Editor

    Allucent, a global mid-sized clinical research organization (CRO), announced today that it received a project award valued at $25.5 million through the Rapid Response Partnership Vehicle (RRPV) Consortium to conduct its Decentralized Home Focus COVID-19 Trial.

  • Roche reports positive Phase Ib results for its du

    Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

    • 16 May 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.

  • SUPERNOVA Phase III trial of sipavibart long-actin

    SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population

    • 16 May 2024
    • Editor

    Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca’s sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population.

  • Recce Pharmaceuticals Reports Positive Preclinical

    Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study

    • 14 May 2024
    • Editor

    Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.

  • Kite and Arcellx Continue Momentum with Advances i

    Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

    • 10 May 2024
    • Editor

    Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.

  • Gentronix recognised with King’s award after recor

    Gentronix recognised with King’s award after record international growth

    • 7 May 2024
    • Editor

    UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets.

  • Boehringer Ingelheim shares positive results from

    Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia​

    • 7 May 2024
    • Editor

    Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).

  • Merck Announces Positive Data for V116, an Investi

    Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults

    • 30 Apr 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain.

  • Bitterroot Bio Announces Dosing of First Participa

    Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers

    • 30 Apr 2024
    • Editor

    Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers.

  • Rilzabrutinib LUNA 3 phase 3 study met primary end

    Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    • 23 Apr 2024
    • Editor

    Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

  • Emerging Trends in Clinical Data Management and Th

    Emerging Trends in Clinical Data Management and Their Impact on Hiring Needs

    • 22 Apr 2024
    • Lucy Walters

    In the rapidly evolving landscape of clinical trials, the role of data manager stands ever more critical at the confluence of innovation, technology, and regulatory compliance.

  • New 48-week frexalimab phase 2 data support potent

    New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

    • 17 Apr 2024
    • Editor

    Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.